Clark note 4/13/05

L5 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:1127329 CAPLUS Full-text
DN 142:74612
TI Preparation of piperazinyl-aryloxy and piperazinyl-heteroaryloxy-N-aryl lactams as 5-HT1B ligands
IN Lowe, John Adams, III; Sanner, Mark Allen
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110994	A1	20041223	WO 2004-IB1942	20040607
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004266781	A1	20041230	US 2004-868055	20040615
PRAI	US 2003-479436P	P	20030618		

OS MARPAT 142:74612
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Ar = Ph, naphthyl, heteroaryl, etc.; Y = H, halo, OH, NO2, CN, etc.; G = alkyl, benzyl, etc.; p = 1-4; Z, W = C, N; n = 1-3] are prepared For instance, 3-[2-(4-Methylpiperazin-1-yl)phenoxy]-1-(4-(trifluoromethyl)phenyl)pyrrolidin-2-one hydrochloride is prepared in 3 steps from 1-(4-trifluoromethylphenyl)pyrrolidin-2-one and 1-(2-hydroxyphenyl)-4-Bocpiperazine. All compds. of the invention show Ki < 100 nM for the 5-HT1B receptor. I are useful for the treatment of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias.

IT **811828-36-1P**, 3-[2-(4-Methylpiperazin-1-yl)phenoxy]-1-(4-bromophenyl)piperidin-2-one **811828-38-3P**, 3-[2-(4-Methylpiperazin-1-yl)phenoxy]-1-[4-(2-oxopyrrolidin-1-yl)phenyl]piperidin-2-one **811828-40-7P**, 3-[2-(4-Methylpiperazin-1-yl)phenoxy]-1-[4-(2-oxooxazolidin-3-yl)phenyl]piperidin-2-one **811828-42-9P**, 3-[2-(4-Methylpiperazin-1-yl)phenoxy]-1-(4-trifluoromethylphenyl)piperidin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(preparation of piperazinyl-aryloxy and piperazinyl-heteroaryloxy-N-aryl lactams as 5-HT1B ligands)

RN 811828-36-1 CAPLUS
CN 2-Piperidinone, 1-(4-bromophenyl)-3-[2-(4-methyl-1-piperazinyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 811828-38-3 CAPLUS
CN 2-Piperidinone, 3-[2-(4-methyl-1-piperazinyl)phenoxy]-1-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 811828-40-7 CAPLUS
CN 2-Piperidinone, 3-[2-(4-methyl-1-piperazinyl)phenoxy]-1-[4-(2-oxo-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 811828-42-9 CAPLUS
CN 2-Piperidinone, 3-[2-(4-methyl-1-piperazinyl)phenoxy]-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:220313 CAPLUS Full-text
DN 140:270743
TI Preparation of heterocyclic amides, in particular azolanes and pyridines as Phosphodiesterase IV (PDE4) inhibitors for the treatment of inflammatory and allergic disorders
IN Thomas, Abraham; Bhavar, Prashant Kashinath; Lingam, V. S. Prasada Rao; Joshi, Neelima Kairatkar
PA Glenmark Pharmaceuticals Limited, India
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004022536	A1	20040318	WO 2003-IB3721	20030903

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI IN 2002-MU804 A 20020904
OS MARPAT 140:270743
GI



I



II

AB The present invention relates to novel heterocyclic compds. that inhibit phosphodiesterase type 4 (PDE 4). The compds. are useful for treating inflammatory conditions, diseases of the central nervous systems and insulin resistant diabetes. Title compds. I [wherein R1 = independently H, (un)substituted alk(en/yn)yl, cyclo/cycloalkyl/aryl/heterocyclyl/hetero aryl/alkyl, cycloalkenyl, aryl, heterocyclyl, etc.; P = a bond, O, S, NR1; P1 = H, halo, OR1, S(:O)R1, C(:O)R1, NO2, etc.; R2 = H, halo, (un)substituted cyclo/alkyl, CN, CH:CH2 and derivs., OH and derivs., CO2H and derivs., etc.; A = (un)substituted aryl, saturated or unsatd. 5-7 membered heterocycle; and their analogs, tautomers, regioisomers, diastereoisomers, stereoisomers, geometrical isomers, N-oxides, polymorphs, and their pharmaceutical acceptable salts and pharmaceutical acceptable solvates] were prepared as phosphodiesterase type 4 (PDE4) inhibitors for treating inflammatory and allergic disorders (no data). For example, II was prepd via acylation of

(3S)-3-Aminoazolane-2,5-dione (preparation given) with 3-Cyclopentyloxy-4-methoxybenzoyl chloride (preparation given), and alkylation of azolane intermediate with cyclopropylmethyl bromide in the presence of CsOH. I were found excellent PDE4 inhibitors in an in vitro study against human PDE4 enzyme (no data). I and their formulations are useful for the treatment of inflammatory allergic diseases, in particular bronchial asthma, allergic rhinitis and nephritis, as well as of diseases of the central nervous system and insulin resistant diabetes (no data).

IT **672883-86-2P**, (3S)-3-[(3-Cyclopentyloxy-4-methoxyphenylcarbonyl)amino]-2-oxo-1-phenylhexahydropyridine
672883-88-4P 672883-90-8P 672883-91-9P,
(3S)-3-[[3,4-Di(difluoromethoxy)phenylcarbonyl)amino]-2-oxo-1-phenylhexahydropyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(Phosphodiesterase IV inhibitor; preparation of heterocyclic amides, in particular azolanes and pyridines, as Phosphodiesterase IV (PDE4) inhibitors for treatment of inflammatory and allergic disorders)

RN 672883-86-2 CAPLUS

CN Benzamide, 3-(cyclopentyloxy)-4-methoxy-N-[(3S)-2-oxo-1-phenyl-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672883-88-4 CAPLUS

CN Benzamide, 3-(cyclopentyloxy)-4-(difluoromethoxy)-N-[(3S)-2-oxo-1-phenyl-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672883-90-8 CAPLUS

CN Benzamide, 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-N-[(3S)-2-oxo-1-phenyl-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672883-91-9 CAPLUS

CN Benzamide, 3,4-bis(difluoromethoxy)-N-[(3S)-2-oxo-1-phenyl-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:20333 CAPLUS Full-text
DN 140:93926
TI Preparation of sulfonylaminovalerolactams as factor Xa inhibitors
IN Smallheer, Joanne M.; Pinto, Donald J.; Wang, Shuaige; Qiao, Jennifer X.; Han, Wei; Hu, Zilun
PA USA
SO U.S. Pat. Appl. Publ., 89 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004006062	A1	20040108	US 2003-429461	20030505
WO 2004041776	A2	20040521	WO 2003-US14142	20030505
WO 2004041776	A3	20040910		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1501798	A2	20050202	EP 2003-808359	20030505

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRAI US 2002-378313P	P	20020506	
WO 2003-US14142	W	20030505	

OS MARPAT 140:93926
GI



I



II

AB The title compds. I [G = Ph, pyridyl, pyrrolyl, etc.; G1 = H, alkyl, acyl, (substituted) amino, etc.; A = (substituted) Ph, carbocyclic, heterocyclyl; B = lactam, heterocyclyl, etc.; n = 0-2] were prepared I can be used as inhibitors of trypsin-like serine proteases, specifically factor Xa. Thus, II is prepared from 1-[4-(3-amino-2-oxopiperidin-1-yl)-3- fluorophenyl]-piperidin-2-one (preparation given) and 6-chloronaphthalene-2- sulfonyl chloride. Pharmaceutical compds. containing I are described.
IT **641612-22-8P 641612-23-9P 641612-24-0P**

641612-25-1P 641612-28-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonylaminovalerolactams as factor Xa inhibitors)

RN 641612-22-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[2-oxo-1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-piperidinyl]-N-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 641612-23-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[2-oxo-1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-piperidinyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 641612-24-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[2-oxo-1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-piperidinyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 641612-25-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[2-oxo-1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-piperidinyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 641612-28-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(2-methyl-4-thiazolyl)methyl]-N-[2-oxo-1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)


Me
S
N
CH2
O
O
S
N
N
N
O
Cl
O

L5 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:928243 CAPLUS Full-text

DN 138:14012

TI Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors

IN Jacobson, Irina C.; Wexler, Ruth R.; Nakajima, Suanne; Quan, Mimi L.; Wang, Shuaige; Smallheer, Joanne M.; Qiao, Jennifer

PA Bristol-Myers Squibb Pharma. Co., USA

SO U.S. Pat. Appl. Publ., 114 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002183324	A1	20021205	US 2001-3125	20011029
	US 6710058	B2	20040323		
	CA 2429113	AA	20021227	CA 2001-2429113	20011030
	WO 2002102380	A1	20021227	WO 2001-US51621	20011030
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1337251	A1	20030827	EP 2001-274110	20011030
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004536084	T2	20041202	JP 2003-504967	20011030
	US 2004132718	A1	20040708	US 2003-730170	20031208
PRAI	US 2000-246107P	P	20001106		
	US 2001-313552P	P	20010820		
	US 2001-3125	A3	20011029		
	WO 2001-US51621	W	20011030		

OS MARPAT 138:14012

GI



I

AB Monocyclic or bicyclic carbocycles and heterocycles and their pharmaceutically acceptable salts are useful as inhibitors of factor Xa in the treatment of thromboembolic diseases. Thus, 1-(4-bromo-2- fluorophenyl)-3-hydroxy-2-piperidinone was treated with 3-NCC6H4OH and the resulting piperidinyloxybenzonitrile was coupled with 2-MeSC6H4B(OH)2 to give the

biphenyl I. Numerous compds. of the invention possessed Ki values of ≤ 10 μM in assays with human factor Xa.

IT **477738-34-4P 477738-43-5P 477738-46-8P 477738-62-8P 477738-72-0P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of biphenylylpiperidinones as factor Xa inhibitors)

RN 477738-34-4 CAPLUS
CN Benzonitrile, 3-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477738-43-5 CAPLUS
CN Benzamide, 3-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-46-8 CAPLUS
CN Benzamide, 4-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)'



RN 477738-62-8 CAPLUS
CN Benzoic acid, 2-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]-5-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 477738-72-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



IT **477738-35-5P 477738-36-6P 477738-37-7P**
477738-38-8P 477738-39-9P 477738-40-2P
477738-42-4P 477738-44-6P 477738-45-7P
477738-47-9P 477738-48-0P 477738-49-1P
477738-50-4P 477738-53-7P 477738-54-8P
477738-56-0P 477738-58-2P 477738-59-3P
477738-60-6P 477738-61-7P 477738-63-9P
477738-64-0P 477738-65-1P 477738-66-2P
477738-67-3P 477738-68-4P 477738-69-5P
477738-70-8P 477738-71-9P 477738-73-1P
477738-74-2P 477738-75-3P 477738-77-5P
477739-03-0P 477739-04-1P 477739-05-2P
477739-07-4P 477739-08-5P 477739-09-6P
477739-12-1P 477739-13-2P 477739-27-8P
477739-34-7P 477740-12-8P 477740-13-9P
477740-14-0P 477740-15-1P 477740-16-2P
477740-17-3P 477740-18-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenylylpiperidinones as factor Xa inhibitors)

RN 477738-35-5 CAPLUS
CN Benzenecarboximidamide, 3-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477738-36-6 CAPLUS
CN Benzenecarboximidamide, 4-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477738-37-7 CAPLUS
CN Benzonitrile, 3-[[1-[2'-[(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477738-38-8 CAPLUS
CN Benzenecarboximidamide, 3-[[1-[2'-[(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477738-39-9 CAPLUS
CN Benzenecarboximidamide, 3-[[1-[2'-[(dimethylamino)methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477738-40-2 CAPLUS
CN Benzenecarboximidamide, 3-[[1-[2'-[(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 477738-42-4 CAPLUS
CN Benzamide, 2,4-dichloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-44-6 CAPLUS
CN Benzamide, 3,4-dichloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-45-7 CAPLUS
CN Benzamide, 4-fluoro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-47-9 CAPLUS

CN Benzamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 477738-48-0 CAPLUS
CN Benzamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 477738-49-1 CAPLUS
CN 4-Pyridinecarboxamide, 2-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-50-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-53-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-

yl]-2-oxo-3-piperidinyl]-6-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 477738-54-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-chloro-, 1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl ester (9CI) (CA INDEX NAME)



RN 477738-56-0 CAPLUS
CN Benzoic acid, 4-methoxy-, 1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl ester (9CI) (CA INDEX NAME)



RN 477738-58-2 CAPLUS
CN Benzaldehyde, 2-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]-5-methoxy- (9CI) (CA INDEX NAME)



RN 477738-59-3 CAPLUS

CN 2-Piperidinone, 3-[(5-chloro-2-pyridinyl)amino]-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477738-60-6 CAPLUS
CN 2-Piperidinone, 1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(4-methoxyphenoxy)- (9CI) (CA INDEX NAME)



RN 477738-61-7 CAPLUS
CN 2-Piperidinone, 1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 477738-63-9 CAPLUS
CN 2-Piperidinone, 3-[3-(aminomethyl)phenoxy]-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477738-64-0 CAPLUS
CN 2-Piperidinone, 1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-[4-

methoxy-2-[(phenylamino)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 477738-65-1 CAPLUS
CN Benzamide, 2-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]-5-methoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 477738-66-2 CAPLUS
CN Benzamide, 3-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 477738-67-3 CAPLUS
CN Benzamide, 4-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477738-68-4 CAPLUS
CN 1H-Indole-5-carboxamide, N-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-69-5 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-70-8 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-71-9 CAPLUS
CN 4-Pyridinecarboxamide, N-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-73-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-74-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-amino-N-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-75-3 CAPLUS
CN 2-Piperidinone, 3-[[(4-chlorophenyl)methyl]amino]-1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477738-77-5 CAPLUS
CN Benzenecarboximidamide, 3-[[[1-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl](phenylmethyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 477739-03-0 CAPLUS
CN 2-Piperidinone, 3-[(3-amino-1,2-benzisoxazol-5-yl)amino]-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477739-04-1 CAPLUS
CN Benzenecarboximidamide, 2-fluoro-5-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 477739-05-2 CAPLUS
CN 2-Piperidinone, 3-[[3-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)phenyl]amino]-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477739-07-4 CAPLUS
CN 2-Piperidinone, 3-[3-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)phenoxy]-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477739-08-5 CAPLUS
CN Benzamide, 3-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-09-6 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477739-12-1 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 477739-13-2 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 477739-27-8 CAPLUS
CN Benzamide, 4-chloro-N-[1-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-(phenylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-34-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477740-12-8 CAPLUS
CN Benzamide, 3-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477740-13-9 CAPLUS
CN Benzenecarboximidamide, 3-[[[1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl](phenylmethyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 477740-14-0 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[2'-[(diethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477740-15-1 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[3-fluoro-2'-(1-pyrrolidinylmethyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477740-16-2 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[3-fluoro-2'-[(3-hydroxy-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477740-17-3 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[3-fluoro-2'-[(4-hydroxy-1-piperidinyl)methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477740-18-4 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[3-fluoro-2'-[[(2-hydroxyethyl)methylamino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **477739-47-2P 477739-57-4P 477739-58-5P**
477739-63-2P 477739-64-3P 477739-65-4P
477740-00-4P 477740-01-5P 477740-21-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of biphenylylpiperidinones as factor Xa inhibitors)

RN 477739-47-2 CAPLUS
CN Benzonitrile, 3-[[1-(4-bromo-2-fluorophenyl)-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477739-57-4 CAPLUS
CN Benzenesulfonamide, N-[1-(4-bromophenyl)-2-oxo-3-piperidinyl]-3-cyano-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477739-58-5 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[3-[[(3-cyanophenyl)sulfonyl](phenylmethyl)amino]-2-oxo-1-piperidinyl]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX

NAME)



RN 477739-63-2 CAPLUS
CN Benzonitrile, 2-fluoro-5-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 477739-64-3 CAPLUS
CN Carbamic acid, (3-amino-1,2-benzisoxazol-5-yl)[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 477739-65-4 CAPLUS
CN Benzonitrile, 3-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 477740-00-4 CAPLUS
CN Benzamide, N-[1-(4-bromophenyl)-2-oxo-3-(phenylmethyl)-3-piperidinyl]-4-chloro- (9CI) (CA INDEX NAME)



RN 477740-01-5 CAPLUS
CN Benzamide, 4-chloro-N-[1-[2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-(phenylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477740-21-9 CAPLUS
CN Carbamic acid, (3-cyano-4-fluorophenyl)[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:754373 CAPLUS Full-text
DN 137:279463
TI Preparation of malonyl amino acid derivatives as inhibitors of the ICE/ced-3 family of cysteine proteases
IN Roggo, Silvio; Hintermann, Samuel; Rasetti, Vittorio; Von Krosigk, Ulrike
PA Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002076968	A1	20021003	WO 2002-EP3194	20020321

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

PRAI GB 2001-7365 A 20010323
OS MARPAT 137:279463
AB Malonyl amino acid derivs. XYNCOCH(V)N(U)COC(T)(S)CONHCH(CH2CO2R)CO-Q [Q = H, fluoromethyl, diphenylphosphinyloxymethyl, halophenyl(carbonyl)oxy(or thio)methyl; R = H, alkyl; S = alkyl, Ph, phenylalkyl; T = H or C(T)(S) = cycloalkyl; U = H, carboxyalkyl, alkyl; V = H, carboxyalkyl and other substituted alkyl, (un)substituted Ph, pyridyl; X = H, alkyl or X with Y forms a -COCH2CH2- bridge or morpholino; Y = alkyl, phenylalkyl, alkoxyalkyl, diphenylmethyl,alkylphenyl, alkoxyphenyl, morpholino, morpholinoalkyl, adamantyl, (un)substituted phenyl] or their salts were prepared as inhibitors of the ICE/ced-3 family of cysteine proteases. Thus, 3-[2-[1-(benzhydrylcarbamoyl)-3-carboxypropylcarbamoyl]-4- methylpentanoylamino]-4-oxobutyric acid was prepared via coupling of 2-(1-tert-butoxycarbonylmethyl-2-oxoethylcarbamoyl)-4-methylpentanoic acid semicarbazone (1) with 4-amino-4-(benzhydrylcarbamoyl)butyric acid tert-Bu ester. Compound 1 was obtained from aspartic acid semicarbazone tert-Bu ester p-toluenesulfonate salt and 2-isobutylmalonic acid monoethyl ester.
IT **464183-19-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(preparation of malonyl amino acid derivs. as inhibitors of the ICE/ced-3 family of cysteine proteases)
RN 464183-19-5 CAPLUS
CN Pentanoic acid, 3-[[[1-[[[2,6-dioxo-1-(3-phenoxyphenyl)-3-piperidinyl]amino]carbonyl]cyclobutyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:549264 CAPLUS Full-text
DN 131:184944
TI Preparation of phenyl and aryl-fused thiazole derivatives as antiviral agents for suppression and treatment of herpes family viral infections and sexually-transmitted viral diseases
IN Flygare, John A.; Jaen, Juan C.; Kearney, Patrick C.; Medina, Julio C.; Sivaraja, Mohanram
PA Tularik Inc., USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9942455	A1	19990826	WO 1999-US2947	19990210
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9932892	A1	19990906	AU 1999-32892	19990210
PRAI US 1998-75224P	P	19980219		
WO 1999-US2947	W	19990210		

OS MARPAT 131:184944
GI



I



II

AB Ph and aryl-fused thiazole derivs. (I) [where X = S, O, NH, or N-lower alkyl; Y = (un)substituted CH or N; or XY = triat. divalent unit of CH, C-alkyl, and N (3 subunits may not all be N); R1 = H, lower alkyl, or taken together with Y forms a 5- or 6-membered ring; R2, R3, and R4 = independently H, (hetero)alkyl, (hetero)arylalkyl, halogen, CN, NO2, (aryl)alkoxy, (un)substituted sulfamoyl, (un)substituted amino, OH, etc.; R5 = H, lower (aryl)alkyl, aryl, (un)substituted amino; with provisos] were prepared as antiviral agents useful in the suppression and treatment of sexually-transmitted viral diseases and herpes family viral infections, especially HSV1, HSV2, Epstein Barr virus, and varicella zoster virus. Thus, 2-iodophenacyl bromide was added to thiourea in dioxane and stirred at room temperature for eight hours to yield 2-amino-4-(2-iodophenyl)thiazole (II). Nine compds. of the invention were tested for antiviral activity using an HSV-1 gel primase assay and exhibited IC50 values ranging from 5 μM to 100 μM.
IT **240136-75-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of Ph and aryl-fused thiazole derivs. as antiviral agents for herpes family viral infections and sexually-transmitted viral diseases)
RN 240136-75-8 CAPLUS

CN 2-Piperidinone, 1-[4-(2-amino-4-thiazolyl)phenyl]-3-[bis(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:296019 CAPLUS Full-text
DN 130:312007
TI A concise synthesis of unnatural (+)-5-epi-nojirimycin-δ-lactam via asymmetric reduction of a meso-imide
AU Kang, Jahyo; Lee, Choon Woo; Lim, Geun Jho; Cho, Byung Tae
CS Department of Chemistry, Sogang University, Seoul, 121-742, S. Korea
SO Tetrahedron: Asymmetry (1999), 10(4), 657-660
CODEN: TASYE3; ISSN: 0957-4166
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 130:312007
AB Nojirimycin-δ-lactam skeleton was synthesized by asym. reduction of a cyclic triacetyloxy meso imide with a chiral β-amino thiol ligand. The resulting product was converted to unnatural (+)-5-epi-nojirimycin- δ-lactam.
IT **223608-78-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(a concise synthesis of unnatural (+)-epi-nojirimycin-δ-lactam via asym. reduction of a meso-imide)
RN 223608-78-4 CAPLUS
CN 2,6-Piperidinedione, 1-(4-methoxyphenyl)-3,4,5-tris(phenylmethoxy)-, (3α,4β,5α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **223608-80-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(a concise synthesis of unnatural (+)-epi-nojirimycin-δ-lactam via asym. reduction of a meso-imide)
RN 223608-80-8 CAPLUS
CN 2-Piperidinone, 6-hydroxy-1-(4-methoxyphenyl)-3,4,5-tris(phenylmethoxy)-, (3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:408893 CAPLUS Full-text
DN 121:8893
TI Phenyl-substituted acrylate ester agrochemical fungicides
IN Mueller, Bernd; Roehl, Franz; Koenig, Hartmann; Sauter, Hubert; Lorenz, Gisela; Ammermann, Eberhard
PA BASF A.-G., Germany
SO Eur. Pat. Appl., 86 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 581095	A2	19940202	EP 1993-111103	19930712
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
	CA 2100546	AA	19940125	CA 1993-2100546	19930714
	JP 06211748	A2	19940802	JP 1993-181305	19930722
	AU 9342121	A1	19940127	AU 1993-42121	19930723
	AU 660226	B2	19950615		
	HU 66105	A2	19940928	HU 1993-2150	19930723
	ZA 9305332	A	19950123	ZA 1993-5332	19930723
PRAI	DE 1992-4224457	A	19920724		

OS MARPAT 121:8893
GI



I



II

AB The title compds. [I; B = (un)substituted alkyl, C1-4 (un)substituted alkenyl, (un)substituted alkynyl, etc.; R1, R2 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, etc.; X, Y = H, halogen, CN, NO2, haloalkyl, alkyl, alkenyl, alkynyl, heteroaryl, heterocyclyl, etc.], useful as agrochem. fungicides, are prepared and I-containing formulations presented. Thus, Me α-(2-hydroxyphenyl)-β-methoxyacrylate was condensed with phenacyl bromide, producing acrylate II, m.p. 76°, which demonstrated 90% inhibitory activity against Plasmopara viticola at 250 ppm.

IT **154594-86-2P 154595-15-0P 154595-16-1P**
154595-17-2P 154595-18-3P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as agrochem. fungicide)

RN 154594-86-2 CAPLUS
CN Benzeneacetic acid, α-(methoxymethylene)-2-[(2-oxo-1-phenyl-3-piperidinyl)oxy]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 154595-15-0 CAPLUS

CN Benzeneacetic acid, α-(methoxymethylene)-2-[[1-(2-methylphenyl)-2-oxo-3-piperidinyl]oxy]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 154595-16-1 CAPLUS

CN Benzeneacetic acid, α-(methoxymethylene)-2-[[1-(3-methylphenyl)-2-oxo-3-piperidinyl]oxy]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 154595-17-2 CAPLUS

CN Benzeneacetic acid, α-(methoxymethylene)-2-[[1-(4-methylphenyl)-2-oxo-3-piperidinyl]oxy]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 154595-18-3 CAPLUS
CN Benzeneacetic acid, 2-[[1-(4-chlorophenyl)-2-oxo-3-piperidinyl]oxy]-α-(methoxymethylene)-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L5 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1975:479038 CAPLUS Full-text
DN 83:79038
TI 1-Phenylpiperidine-2,4,6-trione
AU Mee, John D.
CS Res. Lab., Eastman Kodak Co., Rochester, NY, USA
SO Journal of Organic Chemistry (1975), 40(14), 2135-6
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
OS CASREACT 83:79038
GI For diagram(s), see printed CA Issue.
AB Previous reports of the synthesis of the title compound I were in error; the synthesis of I by hydrolysis of 1-phenyl-4-anilinoglutaconimide (II), obtained by reaction of (EtO2CCH2)2CO with PhNH2, is described.
IT **55267-60-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55267-60-2 CAPLUS
CN 3-Piperidinecarboxylic acid, 2,4,6-trioxo-1-phenyl-5-[(phenylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1964:30878 CAPLUS Full-text
DN 60:30878
OREF 60:5474a-e
TI Reaction of 2-phenyl-4-hexafluoroisopropylidene-5-oxazolone with ketene
AU Rokhlin, E. M.; Gambaryan, N. P.; Knunyants, I. L.
CS Inst. Heteroorg. Compds., Moscow
SO Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1963), (11), 1952-8
CODEN: IASKA6; ISSN: 0002-3353
DT Journal
LA Unavailable
OS CASREACT 60:30878
AB α-Benzamido-β,β-bis(trifluoromethyl)acrylic acid treated with CH2:CO in Et2O in the presence of pyridine (other catalysts failed to give the following product) at -70°, finally 20 min. at -10°, gave 66% β,β- bis(trifluoromethyl) -β- (2- phenyl- 5- hydroxy- 4- oxazolyl)propiolactone (I), m. 142.5-3.5°, which failed to yield any ionic F in 3% KOH at room temperature Reaction run in the presence of NaOAc or BF3.Et2O gave tars, while in the presence of ZnCl2.AlCl3 43% 2-phenyl-4-hexafluoroisopropylidene-5-oxazolone (II) formed, which was also isolated in a low yield from a reaction run in the presence of K2CO3; in the presence of Et3N, an unidentified product, m. 142.5-46° was isolated. The following failed to react with CH2:CO in the presence of pyridine: II, Me α-benzamido-β,β- bis(trifluoromethyl)acrylate, Me β,β- bis(trifluoromethyl)acrylate, Me β,β-bis(trifluoromethyl)vinyl ketone, and 2-phenyl-4-carbethoxy-5-trifluoromethyl-1,3-oxazin-6-one. II kept 50 hrs. at room temperature in aqueous dioxane gave 93% N-benzoyl-β,β- bis(trifluoromethyl)-dl-glutamic acid (III), m. 164-5°, also formed by treatment of I with aqueous Me2CO, aqueous NaHCO3, or concentrated H2SO4 at room temperature I kept 17 days in MeOH gave 31% di-Me N-benzoyl-β,β- bis(trifluoromethyl)-dl-glutamate, m. 77.5-79°, also formed from the free acid and CH2N2. I and PhNH2 in refluxing C6H6 15 hrs. gave N-benzoyl-β,β- bis(trifluoromethyl)-dl-glutamic acid N'-phenylimide, m. 217-18°, unchanged by concentrated H2SO4 at room temperature or by boiling aqueous HCl; it failed to react with CH2:CO in dioxane. I and PhNHNH2 1.5 hrs. in C6H6 gave 74% III N'-phenylhydrazide, m. 206-6.5β. III and CH2:CO in Et2O at room temperature gave 72% III anhydride, m. 190-3°, which dissolved slowly in aqueous NaHCO3, and did not react with CH2N2 or CH2:CO. The filtrate from the anhydride gave 4% same product along with 9% more soluble I. III anhydride refluxed with PhNH2 in dioxane 1.5 hrs. gave PhNHCOCH2C(CF3)2CH(CO2H)NHBz or HO2CCH2C(CF3)2 CH(NHBz)CONHPh, m. 190-90.5° (decomposition).
IT **1960-28-7**, Glutarimide, 2-benzamido-N-phenyl-3,3- bis(trifluoromethyl)-
(preparation of)
RN 1960-28-7 CAPLUS
CN Glutarimide, 2-benzamido-N-phenyl-3,3-bis(trifluoromethyl)- (7CI, 8CI) (CA INDEX NAME)



L5 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1963:462101 CAPLUS Full-text
DN 59:62101
OREF 59:11415a-d
TI The synthesis of 2,4,6-piperidinetrione derivatives
AU Schulte, K. E.; Mang, R.
CS Univ. Muenster, Germany
SO Arch. Pharm. (1963), 296, 501-9
DT Journal
LA Unavailable
OS CASREACT 59:62101
GI For diagram(s), see printed CA Issue.
AB To a solution of 0.2 g.-atom Na in 250 cc. EtOH was added with stirring 0.1 mole malonic ester and 0.125 mole of a malonic acid diamide. The mixture heated 8-10 hrs. at 115° in a pressure bottle and cooled, the solvent removed by distillation to one-half its original volume, and the residue dissolved in H2O and acidified with concentrated HCl gave the following 2,4,6-trioxopiperidine-3-carboxamides (I) (R, R1, R2, % yield, m.p., and recrystn. solvent given): H, H, H, 48, 254-6° (decomposition), --; Me, Me, H, 69, 173-4°, EtOH; Et, Et, H, 60, 91-2°, EtOH-H2O; Pr, Pr, H, 53, 88°, ligroine; Ph, Ph, H, 62, 237°, acetone-H2O; H, Me, H, 55, 244°, EtOH-H2O. Other I prepared using different reagent concns. and exptl. procedures were as follows (same data given): H, H, Et, 23, 176°, EtOH-H2O; H, H, HC.tplbond.CCH2, 33, 214°, EtOH; H, Me, Me, 52, 208°, --; Me, H, Me, 28, 133°, ligroine; Me, Me, HC.tplbond.CCH2, 60.5, 81°, EtOH; Me, Me, HC.tplbond.CCH2, 62, 111°, EtOH; Me, Me, Pr, 86, 88°, --; Ph, Ph, HC.tplbond.CCH2, 54, 135°, EtOH; Ph, Ph, HC.tplbond.CCH2, 45, 133°, EtOH; Ph, Ph, Pr, 85, 129°, EtOH.
IT **94331-29-0**, Nipecotanilide, 2,4,6-trioxo-1-phenyl-
95621-26-4, Nipecotanilide, 2,4,6-trioxo-1-phenyl-5,5-dipropyl-
96669-07-7, Nipecotanilide, 5,5-diallyl-2,4,6-trioxo-1-phenyl-
97085-50-2, Nipecotanilide, 2,4,6-trioxo-1-phenyl-5,5-di-2-propynyl-
(preparation of)
RN 94331-29-0 CAPLUS
CN Nipecotanilide, 2,4,6-trioxo-1-phenyl- (7CI) (CA INDEX NAME)



RN 95621-26-4 CAPLUS
CN Nipecotanilide, 2,4,6-trioxo-1-phenyl-5,5-dipropyl- (7CI) (CA INDEX NAME)



RN 96669-07-7 CAPLUS
CN Nipecotanilide, 5,5-diallyl-2,4,6-trioxo-1-phenyl- (7CI) (CA INDEX NAME)



RN 97085-50-2 CAPLUS
CN Nipecotanilide, 2,4,6-trioxo-1-phenyl-5,5-di-2-propynyl- (7CI) (CA INDEX NAME)



```
=> d l1; d his; log y
L1 HAS NO ANSWERS
L1              STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.



     (FILE 'STNGUIDE' ENTERED AT 18:37:02 ON 13 APR 2005)
                DEL HIS Y

     FILE 'REGISTRY' ENTERED AT 18:43:18 ON 13 APR 2005
L1              STRUCTURE UPLOADED
L2              QUE L1
L3            0 S L2
L4           92 S L2 FUL

     FILE 'CAPLUS' ENTERED AT 18:43:55 ON 13 APR 2005
L5           11 S L4


COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  55.24     219.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -8.03      -8.03

STN INTERNATIONAL LOGOFF AT 18:45:00 ON 13 APR 2005
```

C:\Program Files\Stnexp\Queries\730170.str









chain nodes :
13 14 15 16 17 18 23 25 26 27 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-13 2-14 6-7 14-23 15-16 17-18 25-26 27-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 1-13 2-3 2-14 3-4 4-5 5-6 6-7 14-23 15-16 17-18 25-26 27-28
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

G1:O,N,[*1-*2],[*3-*4],[*5-*6],[*7-*8]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 23:Atom 25:CLASS
26:CLASS 27:CLASS 28:CLASS